

RESEARCH ARTICLE

STEM CELLS AND REGENERATION

Nkx2-5 regulates cardiac growth through modulation of Wnt signaling by R-spondin3

Linda Cambier, Markus Plate, Henry M. Sucov and Mohammad Pashmforoush*

ABSTRACT

A complex regulatory network of morphogens and transcription factors is essential for normal cardiac development. Nkx2-5 is among the earliest known markers of cardiac mesoderm that is central to the regulatory pathways mediating second heart field (SHF) development. Here, we have examined the specific requirements for Nkx2-5 in the SHF progenitors. We show that Nkx2-5 potentiates Wnt signaling by regulating the expression of the R-spondin3 (*Rspo3*) gene during cardiogenesis. R-spondins are secreted factors and potent Wnt agonists that in part regulate stem cell proliferation. Our data show that *Rspo3* is markedly downregulated in *Nkx2-5* mutants and that *Rspo3* expression is regulated by Nkx2-5. Conditional inactivation of *Rspo3* in the *Isl1* lineage resulted in embryonic lethality secondary to impaired development of SHF. More importantly, we find that Wnt signaling is significantly attenuated in *Nkx2-5* mutants and that enhancing Wnt/ β -catenin signaling by pharmacological treatment or by transgenic expression of *Rspo3* rescues the SHF defects in the conditional *Nkx2-5^{+/−}* mutants. We have identified a previously unrecognized genetic link between Nkx2-5 and Wnt signaling that supports continued cardiac growth and proliferation during development. Identification of *Rspo3* in cardiac development provides a new paradigm in temporal regulation of Wnt signaling by cardiac-specific transcription factors.

KEY WORDS: Wnt signaling, R-spondins, Cardiac development, Transcriptional regulation, Angiogenesis, Nkx2-5, *Rspo3*

INTRODUCTION

The spatiotemporal aspects of cardiac development are mediated by interactions of transcription factors and morphogen-mediated signaling pathways that operate in negative- and positive-feedback loops. The mechanism by which signaling pathways, such as Wnt, FGF or Bmp, and transcription factors interact and modulate each others' function is of crucial importance to our understanding of cardiac cell specification and proliferation. Nkx2-5 is one of the earliest known transcription factors required for cardiac cell specification and proliferation. Mice null for *Nkx2-5* die *in utero* at E10 due to circulatory failure (Lyons et al., 1995; Tanaka et al., 1999). Close analysis of the mutant embryos shows arrest of cardiac development at looping stage and selective loss of second heart field (SHF) progenitor cells with absence of right ventricle (RV) and poorly developed outflow tract (OFT). It is generally accepted that *Nkx2-5*, among other genes, such as *Islet1*, *Mef2c*, *Hand2*, *Pitx2*, *Foxh1*, *Fgf8*,

Fgf1 and *Shh* (Buckingham et al., 2005), is required for proliferation and/or patterning of SHF. An equally important observation is that Nkx2-5 is required for distinct phases of cardiac development including specification, differentiation and maintenance of function (Lyons et al., 1995; Tanaka et al., 1999; Habets et al., 2002; Pashmforoush et al., 2004; Jay et al., 2004; Zaffran et al., 2006; Prall et al., 2007). These observations reiterate the significance of a conserved spatiotemporal pattern of *Nkx2-5* gene expression in the context of early cardiac mesoderm specification, proliferation and overall heart tube morphogenesis (Biben and Harvey, 1997; Prall et al., 2007). How *Nkx2-5* expression and function are integrated into morphogen-mediated signaling pathways is currently not clearly understood.

A crucial interaction of Bmp signaling and Nkx2-5 was demonstrated by the Nkx2-5/Bmp2/Smad1 negative-feedback loop that controls heart progenitor specification and proliferation (Prall et al., 2007). In the cardiac fields of *Nkx2-5* mutants, genes controlling cardiac specification and maintenance of the progenitor state, such as *Bmp2*, were upregulated, leading initially to progenitor overspecification, but subsequently failed SHF proliferation and OFT truncation. In the *Nkx2-5* hypomorphic mutant mice, OFT abnormalities were partially rescued by *Smad1* deletion (Prall et al., 2007).

Wnt/ β -catenin signaling has emerged as a key regulator of cardiac progenitor cell specification, and several *in vivo* and *in vitro* studies have examined its function in cardiogenesis (Wu et al., 1995; Schneider and Mercola, 2001; Kwon et al., 2007; Qyang et al., 2007; Ai et al., 2007). Targeted inactivation of β -catenin in the precardiac mesoderm in the SHF using *Isl1Cre* resulted in complete loss of RV and a foreshortened OFT. However, the induction of precardiac mesoderm was not affected. Accordingly, constitutive activation of β -catenin resulted in the expansion of SHF and an enlarged, hypercellular RV (Kwon et al., 2007). These studies provide compelling evidence that this Wnt/ β -catenin pathway plays a positive regulatory role in precardiac and cardiac mesoderm, and furthermore promotes committed cardiac cell proliferation and differentiation.

In vitro studies using embryonic stem cells (ESCs) have provided further evidence for a biphasic role of canonical Wnt signaling in promoting cardiogenic fate (Ueno et al., 2007; Kwon et al., 2007; Wang et al., 2007). Whereas early (prior to mesoderm formation) ectopic Wnt signaling can have inhibitory effects on cardiogenesis, later Wnt signals are essential for cardiogenesis. In this regard, inhibition of canonical Wnt signaling after formation of mesoderm progenitor cells completely abolished beating embryoid bodies (EBs), despite the early presence of Nkx2-5 (Kwon et al., 2007, 2008). These findings point to the crucial role of Wnt/ β -catenin signaling even after initial commitment to the cardiac fate. However, the molecular mechanism by which Wnt signaling promotes expansion of cardiac mesoderm and proliferation of cardiomyocytes is not understood.

Broad Center for Regenerative Medicine and Stem Cell Research, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA.

*Author for correspondence (mpashmfo@usc.edu)

Received 5 September 2013; Accepted 28 May 2014

Here, we show that the conditional loss of *Nkx2-5* in the SHF results in small RV and persistent truncus arteriosus (PTA), and that *Rspo3*, a key mediator of the canonical Wnt signaling, is markedly downregulated in the *Nkx2-5* mutants. Accordingly, we see a reduction of Wnt/ β -catenin signal in the SHF of *Nkx2-5* mutants. Our studies demonstrate that *Rspo3* is a target of *Nkx2-5* and that conditional loss of *Rspo3* resulted in early embryonic lethality secondary to SHF defects. We were able to rescue OFT septation defects in the conditional *Nkx2-5* mutants by *in vivo* pharmacological treatment with LiCl. Similarly, transgenic overexpression of *Rspo3* was able to rescue SHF defects in the *Nkx2-5* mutants. Our studies point to a complex regulatory mechanism by which *Nkx2-5* regulates multiple aspects of cardiac development. We can further unravel a novel pathway by which *Nkx2-5* upregulates Wnt signaling and promotes cardiac cell growth by regulating the expression of *Rspo3*.

RESULTS

Nkx2-5 is required for the proper specification and expansion of SHF progenitors

Nkx2-5⁺ progenitors give rise to the majority of cardiac mesoderm, but the selective role of *Nkx2-5* in the SHF progenitors has not been examined. We inactivated *Nkx2-5* in the pre-cardiac mesoderm using *Isl1-Ires-Cre* (Srinivas et al., 2001; Cai et al., 2003), *Isl1-Cre* (Yang et al., 2006) and *Mef2c-Cre* lines (Verzi et al., 2005). Conditional inactivation of *Nkx2-5* by *Isl1-Cre* or *Mef2c-Cre* resulted in early embryonic lethality at E10-E10.5, which led to a loss of RV and foreshortened OFT (supplementary material Fig. S1). By contrast, inactivation of *Nkx2-5* by *Isl1-Ires-Cre* consistently resulted in perinatal (P1) lethality due to OFT septation defects. Both *Isl1-Cre* and *Isl1-Ires-Cre* lines mediate early recombination very early in the SHF progenitors (Cai et al., 2003; Yang et al., 2006; Sun et al., 2007); however, we found that *Isl1-Cre*-mediated recombination is far more efficient in the SHF than *Isl1-Ires-Cre* (Milgrom-Hoffman et al., 2011). Consistent with *Isl1-Cre* cell lineage studies (supplementary material Fig. S1), we observe that Islet 1 immunoreactive protein is widely present in the SHF

progenitors. Furthermore, coincident expression of *Isl1* and *Nkx2-5* occurred in this region at E9.5 (Fig. 1A-D) (Sun et al., 2007). By contrast, descendants of SHF progenitors from *Isl1-Ires-Cre*-mediated recombination predominantly contributed to the OFT, and less efficiently to the RV (Fig. 1E-J), suggesting that *Isl1-Ires-Cre* effectively labels only a subset of SHF precursors.

All *Nkx2-5* conditional mutants generated by *Isl1-Ires-Cre* showed a small RV with a foreshortened OFT when compared with the heterozygous littermates (Fig. 2A-F). There was a complete penetrance of OFT defects in all mutants examined, which resulted in cyanosis and death within a few hour of birth (Fig. 2F,J). A substantial number (92%) of the mutants analyzed ($n > 140$) demonstrated a single OFT arising from the RV (Fig. 2J), and only a small number of embryos showed double outlet RV (DORV). The compound heterozygotes of *Nkx2-5* and *Isl1* were all viable and recovered at the expected Mendelian ratio. Gross examination and histology showed no evidence of OFT or RV abnormalities in the heterozygotes. Examination of *Nkx2-5* mutants on the *R26R-lacZ* background revealed that *lacZ*⁺ cells contributing to the RV and OFT are substantially reduced (Fig. 2G-J).

Defective trabeculae and endocardial cushions in the *Nkx2-5* mutants

In the conventional *Nkx2-5* mutants the early cardiac tube was formed but endocardial cushions and trabeculae were distinctly absent. These findings suggest that *Nkx2-5* is required for certain phases of myocardial growth and proliferation, as well as interaction of myocytes with the adjacent non-myocardial tissue (Lyons et al., 1995; Tanaka et al., 1999). Histological examination of the *Isl1-Ires-Cre; Nkx2-5*^{f/f} mutants (from here on referred to as conditional *Nkx2-5* mutants) similarly showed a marked reduction of trabecular networks in the RV, whereas the left ventricle (LV) was spared (Fig. 3A-D, arrows). Furthermore, we noted smaller developing endocardial cushions in the proximal OFT (Fig. 3B,D). In this regard, *Nkx2-5* immunoreactive protein was predominantly absent in the RV and OFT, but consistently present in the LV of the mutant




Fig. 1. Fate map of *Isl1-Ires-Cre* in *R26R-lacZ* reporter mice.

(A-D) Immunofluorescence analysis on sagittal sections of E9.5 embryos shows the presence of *Isl1* in the SHF and the colocalization of *Nkx2-5* and *Isl1* in the OFT precursors (arrows). (E-J) X-gal staining of whole-mount (E,H) and sections (F,G,I,J) of embryos from *Isl1-Ires-Cre* crossed with *R26R-lacZ* reporter line showing efficient recombination in a subset of SHF precursors that contribute to OFT myocardium at E10.5 (E-G) and E12.5 (H-J). By contrast, RV myocytes are not labeled efficiently (F,I). A, atrium; LV, left ventricle; OFT, outflow tract; RV, right ventricle; SHF, second heart field.




Fig. 2. Cardiac defects in the conditional *Nkx2-5* mutants. Compared with the heterozygous littermates (A,C,E), conditional mutants of *Nkx2-5* by *Isl1^{flox}-Cre* display a single OFT and a considerably smaller RV (B,D,F) at E12.5. Examination of *Nkx2-5* mutants and littermate controls at E10.5 (G,H, $n=4$) and P1 (I,J, $n=5$) on *R26R-lacZ* background shows reduced number of *lacZ*⁺ cells in the RV and OFT of mutant hearts. However, compared with RV, a large number of *lacZ*⁺ cells are still present in the mutant OFT. Ao, aorta; LA, left atrium; LV, left ventricle; OFT, outflow tract; PA, pulmonary artery; PTA, persistent truncus arteriosus; RA, right atrium; RV, right ventricle.

embryos at E12.5, suggesting at least a cell-autonomous role for *Nkx2-5* in this region (supplementary material Fig. S2).

To further confirm these findings, we next examined the formation of trabecular networks and OFT cushions in mutant hearts by immunofluorescence staining for CD31 antigen (Pecam1). We similarly observed a marked reduction of trabeculae and endocardial networks in the conditional mutant RV (Fig. 3E,F; $n=7$). Examination of the proximal OFT (arrows) in mutants showed defective endocardial networks, whereas the neural crest cell-derived distal OFT endocardial cushions appeared relatively unperturbed (Fig. 3G,H, arrowheads; $n=7$). Examination of the mutant hearts by apoptotic markers (TUNEL assay) failed to show a difference compared with the heterozygous littermates (data not shown). By contrast, examination of the trabecular myocardium and OFT cushions, but not the compact myocardium, by phospho-histone-H3 immunostaining (and 5-bromo-2-deoxyuridine, BrdU; data not shown) showed a statistically significant reduction in the relative proliferative rate in the mutant embryos (Fig. 3I-O) (Prall et al., 2007). The decrease in the relative proliferative rate of SHF was evident as early as E10, which ultimately resulted in hypoplastic RV and OFT in the mutants at E12.5 (Fig. 3K,N). Consistent with prior studies, these observations suggest that *Nkx2-5* is a crucial factor in the formation of the trabecular myocardium and OFT cushions (Waldo et al., 2001; Jiang et al., 2000; Prall et al., 2007).

In our studies, we did not find a significant change in either *Bmp2* or *Bmp4* expressions in the conditional *Nkx2-5* mutants. Therefore, ectopic expression of *Bmp2* in the conventional *Nkx2-5* mutants might be dependent on spatial and/or temporal factors that are not present in our conditional model (Prall et al., 2007). In support of this notion, examination of the compound conditional mutants of *Bmp2* and *Nkx2-5* did not show a change in the phenotype of the conditional *Nkx2-5* mutants (supplementary material Figs S3 and S4).

Gene expression profile in the RV/OFT of the *Nkx2-5* mutants

To gain further insight into the molecular basis of *Nkx2-5* functions in the SHF, we examined the mutant and heterozygous littermates by gene expression microarray on two independent sample pairs and subsequently performed quantitative RT-PCR on ten independent sample pairs (Fig. 4A,B). In agreement with previously reported findings (Pashmforoush et al., 2004; Prall et al., 2007), we noted

that several genes, including *Hcn4*, *Odz4*, *Tbx3* and *Pdgfra*, were upregulated in the RNA isolated from RV/OFT of conditional *Nkx2-5* mutants. Strikingly, we observed that some of the key regulators of Wnt signaling pathway were altered in the *Nkx2-5* mutants (Fig. 4B). Among these, *Rspo3*, a secreted factor and a reported potent agonist of Wnt signaling, was significantly diminished in the conditional *Nkx2-5* mutants. *Rspo3* is the predominant member of the R-spondin gene family (1-4) that is initially expressed in the embryonic heart at around E8.5, whereas other R-spondin members showed very low expression levels (Nam et al., 2007; Aoki et al., 2007; Kazanskaya et al., 2008). Further expression analysis of several other secreted factors, including *Wnt11*, *Wnt5*, *Wnt8*, *Fgf8*, *Fgf10*, *Bmp2* and *Bmp4*, failed to show a significant change in mRNA levels by qRT-PCR in several independent mutants examined (supplementary material Fig. S5).

Several studies have pointed to the inductive interaction of cardiac neural crest cells and SHF progenitors in the septation of the OFT (Kirby et al., 1985; Kirby and Waldo, 1995; Zaffran et al., 2004). We therefore examined the expression of several key factors implicated in the development and septation of OFT by *in situ* hybridization. semaphorin 3C (*Sema3C*) is expressed in the OFT/subpulmonary myocardium (Feiner et al., 2001), whereas plexin A2 (*Plxna2*), a receptor for semaphorin signaling, is expressed in the cardiac neural crest cells (CNCC; Brown et al., 2001). *Plxna2* transcripts were present at a reduced level in the OFT by section and whole-mount *in situ* hybridization (Fig. 4C-F). We also noted that expression of *Sema3C* was markedly diminished in the mutant hearts (Fig. 4G-J). We did not observe an appreciable difference in *Wnt11*, *Wnt5* or *Tgfb2* expression in the mutant hearts at E10.5 (Fig. 4K-R). Our data suggest that loss of *Nkx2-5* negatively impacts myocardial:CNCC interaction, thus contributing to OFT septation defects seen in the *Nkx2-5* mutants.

Rspo3 is markedly downregulated in the *Nkx2-5* mutants

R-spondin3 is a member of the R-spondin gene family (*Rspo1-4*), a group of secreted Wnt signaling agonists that regulate embryonic patterning and stem cell proliferation (Kazanskaya et al., 2004, 2008; de Lau et al., 2011; Glinka et al., 2011). Gene expression analyses indicated that *Rspo3* is markedly downregulated in the *Nkx2-5* mutants. To validate these observations, we examined




Fig. 3. Conditional *Nkx2-5* mutants show selective loss of RV trabeculae and endocardial cushions. (A–D) Hematoxylin and Eosin (H&E) staining of paraffin sections show poorly developed trabeculae and endocardial networks in the RV of the mutant hearts at E11.5, whereas the LV is relatively preserved. (E–H) Similarly, immunofluorescence staining for Pecam1 shows significant loss of trabeculae in the mutant RV (E, F, arrows) and diminished endocardial networks in the conotruncus (G, H, arrowheads) at E9.5. (I, J, L, M) Immunofluorescent analysis for pHH3 (I, L) and for α -actinin (J, M). Mutant hearts show diminished relative cell proliferation in the trabeculae and endocardial cushions as assessed by pHH3 immunostaining. (K, N) At E12.5, the mutant hearts show hypoplastic cushions in the OFT (arrows; $n=5$). (O) Statistical analyses show a significant reduction of the relative cell proliferation in the trabecular myocardium and OFT cushions at E10.5 ($n=7$; $**P=0.014$). α -act, α -actinin; A, atrium; OFT, outflow tract; RV, right ventricle.

the expression of *Rspo3* by *in situ* hybridization. *Rspo3* is expressed at low levels in the developing heart at E8.5. However, at E9.5 to E10.5, *Rspo3* is predominantly seen in the AV canal and the OFT, whereas lower levels are detectable in the entire heart including atria and ventricles (Fig. 5A–H) (Nam et al., 2006, 2007; Aoki et al., 2007; Kazanskaya et al., 2008). In late gestation, expression of *Rspo3* becomes restricted to the sites of active Wnt signaling, such as cardiac valves and the myocardium just adjacent to the valvular apparatus (supplementary material Fig. S6). By *in situ* hybridization we noted marked reduction of *Rspo3* transcripts in the RV and OFT of the conditional *Nkx2-5* mutants (Fig. 5I–P, arrows; $n=8$). Examination of the conventional *Nkx2-5* mutants similarly showed reduced *Rspo3* expression in the mutant SHF (white arrows) and OFT (black arrows) at E9 (Fig. 5Q–S; $n=4$). To further confirm these findings, we micro-dissected RV and OFT from conditional KO ($n=5$) and from their littermate controls ($n=3$) at E10.5 and subjected them to semi-quantitative (Fig. 5T) and quantitative (Fig. 5U) RT-PCR analysis. The conditional *Nkx2-5* mutants have a marked reduction in the *Rspo3* transcripts compared with heterozygous controls (Fig. 5T–U). These observations provide support for a genetic link between *Nkx2-5* and *Rspo3* in the developing heart.

Rspo3 is directly regulated by *Nkx2-5*

To determine whether *Nkx2-5* can directly regulate the expression of *Rspo3* in the developing heart, we performed an *in silico* analysis of *Rspo3* and identified multiple potential *Nkx2-5* binding sites in the immediate 5'-region of the gene by using BLAST and VISTA analyses (Fig. 6A, B) (Altschul et al., 1990; Mayor et al., 2000). Among the putative *Nkx2-5* binding sites, we identified a site in a highly conserved region of the 5'-regulatory sequence conserved from

chick to human (Fig. 6B). To test the functionality of the *Rspo3* enhancer *in vivo*, we first generated transient transgenic mice harboring the immediate 5 kb upstream of *Rspo3* (from ATG codon) that were cloned upstream of an *Hsp68-lacZ* reporter plasmid (Kothary et al., 1989). Such analysis revealed that three out of the five embryos carrying the transgene demonstrated β -galactosidase activity in the developing heart at E10.5 (Fig. 6C). The 5 kb enhancer sequences also drove the expression of *lacZ* in the pharyngeal arches, otic vesicles and the neural tube, sites consistent with *in situ* hybridizations for *Rspo3* (Aoki et al., 2007; this study).

To determine whether *Nkx2-5* can directly bind the *Rspo3* regulatory sequences, we examined the conserved 5'-region of the *Rspo3* gene by chromatin immunoprecipitation (ChIP) using *Nkx2-5* antibody. Six potential *Nkx2-5* binding sites were identified and subsequently examined by qPCR analysis of the immunoprecipitated chromatin. Among these, site 3 (–2704 bp from ATG codon), which is located in the highly conserved region, showed statistically significant enrichment by ChIP assay (Fig. 6D, E). To confirm further whether site 3 is a potential *Nkx2-5* binding site, we examined the ability of *Nkx2-5* expressed protein to bind these sequences by electrophoretic mobility shift assays (EMSA). Using radiolabeled oligos containing the putative *Nkx2-5* binding sequences at site 3, we consistently observed that the electrophoretic mobility shift of *in vitro* translated *Nkx2-5* in these assays (Fig. 6F).

We next tested the ability of *Nkx2-5* to activate the *Rspo3* promoter in 293T cell transfection luciferase assays. Accordingly, we found that plasmids harboring DNA fragments, which contained site 3, demonstrated robust activation by *Nkx2-5* (Fig. 6G). Mutation of the putative *Nkx2-5* consensus sequence in site 3 abolished activation by *Nkx2-5* in luciferase assays. We next generated transient transgenic




Fig. 4. Altered gene expressions in the *Nkx2-5* mutant hearts. (A) RV and OFT were dissected from the conditional mutants ($n=12$) and control littermates ($n=11$) at E10.5. (B) qRT-PCR analysis showing selected genes with statistically significant variations ($*P<0.05$; $**P<0.01$) in expression between mutants and control littermates. (C–J) Whole-mount and section *in situ* hybridization for *PlxnA2* (C–F) and for *Sema3C* (G–J) showing reduced expression levels (arrows and arrowheads) in the mutants compared with controls. *In situ* hybridizations show similar levels of expression for *Wnt11* (K,L, arrows), *Wnt5* (M,N, arrows) and *Tgfβ2* (O–R, arrowheads) in the mutant and control embryos at E10.5. CKO, *Nkx2-5* mutants; Het, heterozygous control; LV, left ventricle; OFT, outflow tract; RV, right ventricle.

mice harboring the 290 bp conserved region (including site 3) upstream of the *Hsp68-lacZ* gene. Transient transgenic assays showed β -galactosidase expression in the heart of four out of seven embryos harboring the transgene (Fig. 6H,I). These results provide further evidence that *Nkx2-5* can directly regulate the expression of *Rspo3* *in vitro*. Collectively, our data support direct regulation of *Rspo3* by *Nkx2-5*. In agreement with our data, a recent study showed loss of expression of *Rspo3* in *Nkx2-5*-deficient mouse ESCs. By contrast, overexpression of *Nkx2-5* in the ESCs led to a marked increase in expression of *Rspo3* (Nakashima et al., 2009).

Wnt/ β -catenin signaling is diminished in the *Nkx2-5* mutants

Several studies have demonstrated that canonical Wnt signaling is essential for normal cardiac development and that the conditional loss of β -catenin in the SHF leads to profound cardiac defects (Ai et al., 2007; Klaus et al., 2007; Lin et al., 2007; Kwon et al., 2007). We hypothesized that loss of *Rspo3* and dysregulation of Wnt signaling is one of the potential mechanisms that can lead to SHF defects in the *Nkx2-5* mutants. We assessed the extent of Wnt signaling by crossing TOPGAL and BATGAL reporter lines into the conditional and conventional *Nkx2-5* mutants, respectively. Examination of the conditional (TOPGAL; Fig. 7A–C) and conventional (BATGAL; Fig. 7E–G) *Nkx2-5* mutants on the Wnt reporter backgrounds showed a reduced number of *lacZ*⁺ cells in the OFT and pharyngeal arches (sites of expression of *Nkx2-5* and *Isl1*) in the conditional and conventional *Nkx2-5* mutants. We quantified the number of *lacZ*⁺ cells in tissue sections of the conditional *Nkx2-5* mutant embryos ($n=6$). These analyses revealed a 32%

reduction in the number of *lacZ*⁺ cells in mutant OFT compared with heterozygous littermates.

To further validate these observations, we examined the expressions of known targets of Wnt signaling, including *Isl1* and activated β -catenin, in the SHF of the *Nkx2-5* mutants (Lin et al., 2007; Cohen et al., 2007). We used a combination of immunofluorescence staining and *in situ* hybridization to identify *Isl1*⁺ and activated β -catenin⁺ cells in the conditional *Nkx2-5* mutants (Fig. 7H–O) (Rhee et al., 2007). At E10.5, during proliferation and deployment of the SHF progenitors in the OFT, we observed a significant reduction in the number of *Isl1*⁺ and activated β -catenin⁺ nuclei in the conditional *Nkx2-5* mutants (Fig. 7L,M; $n=5$ mutants analyzed). Further examination of the conditional *Nkx2-5* mutants by section *in situ* hybridization also confirmed reduced *Isl1* expression in the OFT in the mutants (Fig. 7N,O). These data support the contention that canonical Wnt signaling is reduced in the SHF of *Nkx2-5* mutants.

R-spondin3 is required for the proper development of SHF

Conditional inactivation of β -catenin by *Isl1-Cre* was previously shown to result in embryonic lethality at E12.5 secondary to cardiac and pharyngeal arch artery defects (Lin et al., 2007; Kwon et al., 2007). We hypothesized that the phenotype in the *Nkx2-5* mutants could be in part due to the loss of *Rspo3* and attenuation of Wnt signaling in the SHF. Prior studies have shown that *Rspo3* null mutants are growth retarded and die at E10 due to placental and global vascular defects (Aoki et al., 2007; Kazanskaya et al., 2008). The early embryonic lethality precluded examination of later cardiac development in *Rspo3* null mice. To circumvent this problem, we




Fig. 5. *Rspo3* expression is significantly reduced in *Nkx2-5* mutants. (A-H) Whole-mount *in situ* hybridization in E8.5-E10.5 embryos show that *Rspo3* is highly expressed in the tail bud and neural tissue. Lower levels of *Rspo3* transcripts are detected in the SHF (arrow in B) and the rest of the developing heart (arrow in D). At E10.5, *Rspo3* is highly expressed the AV canal and the OFT (arrow in F). (I-P) Whole-mount and section *in situ* hybridization showing markedly diminished expression of *Rspo3* (arrows) in the *Nkx2-5* mutant OFT at E9.5 and E10.5. (Q-S) Whole-mount *in situ* hybridizations showing markedly diminished *Rspo3* expression in the RV/OFT (black arrows) and SHF/pharyngeal arches (white arrows) of the *Nkx2-5* conventional mutants. (T) Semi-quantitative and (U) quantitative RT-PCR showing markedly diminished *Rspo3* transcripts in the conditional mutant hearts ($P=0.0008$). LA, left atrium; LV, left ventricle; OFT, outflow tract; RA, right atrium; RV, right ventricle.

crossed mice carrying the conditional allele of *Rspo3* (Kazanskaya et al., 2008) with *Isl1-Ires-Cre* mice and *Isl1Cre* lines. Conditional inactivation of *Rspo3* by *Isl1-Ires-Cre* resulted in late gestational lethality (E14.5-16.5) in most mutants secondary to cardiovascular failure. All mutant embryos analyzed had evidence of small RVs and/or DORV (supplementary material Fig. S7).

By contrast, inactivation of *Rspo3* by the more efficient *Isl1-Cre* line resulted in uniform embryonic lethality at E11.5 (>100 mutants analyzed; from here on referred to as *Rspo3* mutants). All *Rspo3* mutants demonstrated pericardial edema and marked vascular congestion, evidence of early circulatory failure (Fig. 8A,E). Histological analysis of *Rspo3* mutant hearts consistently revealed defects of RV and OFT, consisting of hypocellular cushions and a thin-walled myocardium (Fig. 8B-H). The heterozygous littermates were recovered in the expected Mendelian ratio without any noticeable abnormality. The cardiac defects in *Rspo3* mutants were evident as early as E10, when myocardial wall thickness was diminished in the mutant embryos (data not shown). Immunofluorescence analysis of the mutant hearts by anti-CD31 and anti- α -actinin antibodies suggested proper specification of myocardial and endocardial lineages in the *Rspo3* mutants (Fig. 8I-P). We next examined the

proliferation rate in the mutant embryos by immunostaining for phospho-histone H3 (pHH3) (Fig. 8K,O) and BrdU (Fig. 8Q). These independent studies showed reduced relative proliferation rates in the *Rspo3* mutant hearts. These results are thus consistent with the suggested role of Wnt/ β -catenin signaling in cardiac progenitor cell proliferation (Kwon et al., 2007, 2008).

To further explore the role of *Rspo3* as a positive modulator of Wnt signaling, we tested the ability of *Rspo3* to drive the expression of the Tcf/Lef luciferase reporter system in mouse ESCs (Biechele et al., 2009). ESCs were transfected with Tcf/Lef luciferase reporter plasmids and after 24 h were treated with Wnt3a and/or *Rspo3* recombinant proteins. These experiments demonstrated the potent ability of *Rspo3* in activating canonical Wnt signaling and further showed that *Rspo3* synergizes with Wnt3a in activating the β -catenin protein (Fig. 8R,S). The activation of the Tcf/Lef reporter was promptly abolished by addition of Dkk1, thus showing the specificity of *Rspo3* in activating the canonical Wnt pathway (Fig. 8R).

Several studies have indicated a positive role for the canonical Wnts in promoting cardiogenesis in ESC-derived embryoid bodies (EBs; Ueno et al., 2007; Kwon et al., 2007). To this end, we used previously described methods (Kwon et al., 2007) to test whether




Fig. 6. Nkx2-5 directly regulates *Rspo3* expression. (A) Schematic representation of the *Rspo3* locus showing the relative positions of the six putative Nkx2-5 binding sites (red arrows) and ChIP PCR primers (black arrows). (B) The position of site 3 in the *Rspo3* promoter is highlighted and shows marked conservation across species. The putative Nkx2-5 and Mef2c binding sites in close proximity are shown. (C) The cloned 5 kb promoter construct drives the expression of *Hsp68-lacZ* reporter transgene in the embryonic heart and pharyngeal arches at E10.5 (white arrows). Three out of five transient transgenic embryos showed β -galactosidase staining that closely resembles the *in situ* hybridization. (D,E) ChIP showing that site 3 is highly enriched compared with the other sites. ChIP assays were repeated three times in triplicate assays ($P < 0.01$). (F) EMSA demonstrating specific binding of Nkx2-5 to oligos containing Nkx2-5 binding sequences in site 3. (G) Luciferase assays in transient transfections of 293T cells showing that a 3 kb fragment upstream of ATG codon is significantly activated by Nkx2-5. The 460 bp (position -2505 to -2965) and 290 bp (-2505 to -2795) fragments containing site 3 are also activated by Nkx2-5 co-transfection. The expression vector containing a mutated Nkx2-5 binding site in the *Rspo3* promoter is not activated by co-transfection with Nkx2-5 expression vector. (H,I) Four out of seven transient transgenic embryos harboring the 290 bp fragment showed expression of the *Hsp68-lacZ* reporter in the heart (arrow in H), whereas only one out of six transgenic embryo carrying the mutated Nkx2-5 binding site did not show β -galactosidase expression (arrow in I).

Rspo3 can positively influence cardiogenesis in EBs derived from mouse ESCs. We treated mouse ESCs (R1) with *Rspo3* recombinant protein on days 3-5 of differentiation, and subsequently collected EBs at days 5 and 6. Quantitative RT-PCR analysis of RNA derived from *Rspo3*-treated ESCs consistently showed that *Rspo3* potentiates the expression of the cardiogenic fate markers *Islet1* and *Nkx2-5* (Fig. 8T,U). Therefore, our studies point to *Rspo3* as a positive modulator of cardiogenic fate in mouse ESCs.

Activation of canonical Wnt signaling rescues SHF defects in the *Nkx2-5* mutants

Our data suggested that loss of *Nkx2-5* negatively impacts the extent of Wnt signaling in the SHF by downregulating the expression of *Rspo3*. Furthermore, *Rspo3* is a crucial modulator of Wnt signaling required for cardiac development. To determine whether temporal activation of Wnt/ β -catenin signaling can rescue the phenotype in the *Nkx2-5* mutants, we chose a pharmacological approach using LiCl, an inhibitor of Gsk3 β and potent activator of Wnt/ β -catenin

pathway (Klein and Melton, 1996; Nakamura et al., 2003; Tian et al., 2010). We administered LiCl or NaCl (control) once a day intraperitoneally to pregnant females (*Isl1^{Cre}; Nkx2-5^{f/wt} × Nkx2-5^{f/f}*) from E8 to E10 at the time of expansion and proliferation of SHF. Whereas all mutant neonates born to females treated with NaCl had a small RV and a single OFT ($n=12$), the majority of the mutants (10/15, 67%) born to females treated with LiCl showed a significantly larger RV and drastic septation of the OFT (Fig. 9). However, treatment with LiCl failed to correct the alignment defects of the OFT in the *Nkx2-5* mutant embryos (Fig. 9E). These data show that loss of *Nkx2-5* leads to attenuation of the Wnt/ β -catenin pathway and that pharmacological activation of Wnt signaling can significantly ameliorate the phenotype in the conditional *Nkx2-5* mutants.

Conditional expression of *Rspo3* rescues *Nkx2-5* mutants

We next sought to determine whether gain-of-function of *Rspo3* could rescue the SHF phenotype in the *Nkx2-5* mutants. To this end, we




Fig. 7. Decreased Wnt- β -catenin signaling in the SHF of the conditional *Nkx2-5* mutants. (A-C) Whole-mount and section X-gal staining of the conditional *Nkx2-5* mutants on the TOPGAL background showing statistically significant diminished number of *lacZ*⁺ cells in the pharyngeal arches and OFT (black arrows) of the E9.5 mutant embryos ($n=9$ embryos). (D) Quantification of *lacZ*⁺ cells in mutants and control OFT ($n=6$; $**P<0.01$). (E-G) X-gal staining of the conventional *Nkx2-5* mutants (*Nkx2-5^{cre/cre}*, *Nkx2-5* Null) and heterozygous (*Nkx2-5^{cre/+}*, HET) embryos on the BATGAL reporter background, showing significant reduction of *lacZ*⁺ in the developing OFT of *Nkx2-5* null embryos (black arrows; $n=10$). (H-K) Immunofluorescence staining showing reduced number of *Isl1*⁺ (H,I, arrows) and activated β -catenin⁺ (J,K, arrows) cells in the SHF of controls (*Isl1-Ires-Cre* \times *Nkx2-5^{f/w}*; $n=4$) and mutants (*Isl1Cre* \times *Nkx2-5^{ff}*; $n=6$) at E10.5. Quantitation of *Isl1*⁺ (L) and activated β -catenin⁺ (M) cells shows statistically significant reduced number of cells in the mutant sections (10 μ m). (N,O) *In situ* hybridization showing diminished expression of *Isl1* in SHF of the *Nkx2-5* mutants (*Isl1Cre* \times *Nkx2-5^{ff}*) at E10.5. OFT, outflow tract; PE, pharyngeal endoderm.

generated transgenic mice that conditionally express *Rspo3* after they are crossed with a Cre-driver line (Fig. 10A,B). Conditional overexpression of *Rspo3* transgene (*Rspo3^{OE}*) using an *Isl1-Ires-Cre* line resulted in embryonic lethality in most transgenic embryos at mid-gestation (9/10 at E11.5), and we were unable to recover any newborns (Fig. 10C). These results suggest that excess Wnt signaling mediated by *Rspo3* results in embryonic lethality (Fig. 10B). These data are consistent with prior studies that also demonstrated that constitutive activation of Wnt/ β -catenin signaling in cardiac mesoderm results in early embryonic lethality (Kwon et al., 2007; Grigoryan et al., 2008). Surprisingly, when the *Rspo3^{OE}* line was crossed into the conditional *Nkx2-5* line (*Isl1^{fres-Cre}; Nkx2-5^{f/w} \times Rspo3^{OE}; Nkx2-5^{ff}*), we were able to recover the majority of *Rspo3^{OE}* neonates on the *Nkx2-5* mutant background (Fig. 10C,F). Therefore, it appears that loss of *Nkx2-5* in the precardiac mesoderm attenuates excess Wnt signaling in *Rspo3*-overexpressing embryos. We next examined the conditional *Nkx2-5* mutants that carried the *Rspo3^{OE}* transgene. Examination of *Rspo3^{OE}* neonates on the *Nkx2-5* mutant background in several litters consistently showed that selective activation of *Rspo3* in the SHF by *Isl1-Ires-Cre* rescues the SHF defects of the conditional

Nkx2-5 mutants and results in a larger RV and septation of the OFT (Fig. 10D-L). Our data provide further evidence for the genetic interaction between *Nkx2-5* and Wnt signaling in the SHF.

DISCUSSION

Recent data have identified that Wnt/ β -catenin signals control distinct sets of transcription factors in cardiac progenitor cells (Klaus et al., 2012). Here, we find a genetic link between *Nkx2-5* and Wnt signaling that is mediated by *Rspo3*. We show that *Nkx2-5* is required for the expansion of SHF progenitors and that loss of *Nkx2-5* in the SHF is associated with loss of RV and defects of OFT septation. In our study, conditional mutants of *Nkx2-5* generated by *Mef2cCre* and *Isl1-Cre* lines display early embryonic lethality with a virtually absent RV and a foreshortened OFT, consistent with defects of SHF development (supplementary material Fig. S1). By contrast, mutants generated by *Isl1-Ires-Cre* survived to term with a smaller RV being present. It has previously been shown that *Isl1-Ires-Cre* is active very early in precardiac mesoderm and that it acts upstream of *Mef2c* (Cai et al., 2003; Dodou et al., 2004; Verzi et al., 2005). The data presented here suggest that it is the efficiency of the *Cre* lines in the SHF that results in




Fig. 8. *Rspo3* is essential for cardiac development. (A-H) Conditional inactivation of *Rspo3* by *Isl1Cre* resulted in embryonic lethality at E11.5. The mutant embryos show evidence of vascular congestion and pericardial edema (A,E). H&E sections of the *Rspo3* mutants (*Isl1^{Cre}; Rspo3^{fl/fl}*) and heterozygotes (*Isl1^{Cre}; Rspo3^{fl/w}*) show poorly developed RV and OFT in the mutant embryos. (I-P) Examination of *Rspo3* mutants by immunofluorescence for α -actinin, phospho-histone-H3 and *Pecam1* (CD31) shows a poorly developed heart. Endocardium and myocardium appear to be specified properly. (Q) Quantitation of cell proliferation, as assessed by BrdU, shows a statistically significant reduction of the relative proliferation rate in cardiomyocytes of the mutant hearts (Ko) compared with wild type (Het). (R) *Rspo3* potentiates canonical Wnt signaling in mouse ESCs transfected with *Tcf/Lef* reporter plasmid. *Rspo3* activation of *Tcf/Lef* reporter plasmid is inhibited by *Dkk1*. (S) Western blot showing a significant increase in activated β -catenin in EBs (day 5) derived from ESCs treated with *Wnt3a* and/or *Rspo3*. (T,U) Mouse ESCs were treated (days 3, 4) with *Wnt3a*- or *Wnt3a/Rspo3*-conditioned media in the presence or absence of *Dkk1*. RNA was isolated from EBs at day 6 and was subjected to qRT-PCR for *Isl1* and *Nkx2-5* transcripts. *Rspo3* potentiates *Wnt3a* by significantly increasing *Isl1* and *Nkx2-5* transcripts in EBs.

the observed phenotypes, and not necessarily a temporal difference. To this end, we observed that *Isl1-Ires-Cre*-mediated recombination is very efficient in the SHF progenitors that ultimately contribute to the myocardium of the OFT, whereas recombination in progenitors that contribute to RV is modest (Figs 1 and 2). We find that *lacZ⁺*, *Nkx2-5*-deficient cells are predominantly present in the myocardium of OFT compared with RV (supplementary material Fig. S1J,M and Fig. S2I,J), suggesting that *Nkx2-5* might not be as crucially required in this population of cardiomyocytes. The predominant presence of *Nkx2-5⁻* cells in the OFT, but not RV, raises the interesting possibility that requirements for *Nkx2-5* are not uniform in the SHF progenitors.

***Nkx2-5* regulates *Rspo3* expression and modulates Wnt signaling**

Perturbation of both canonical and non-canonical Wnt signaling affects the development of SHF-derived structures resulting in RV and OFT defects. Conditional mutants of β -catenin and *Lrp6* in the

canonical pathway, as well as *Wnt5a* and *Wnt11* in the non-canonical pathway, result in OFT defects in mice (Kwon et al., 2007; Lin et al., 2007; Schleiffarth et al., 2007; Zhou et al., 2007; Song et al., 2010). In the present study, we provide evidence that *Nkx2-5* is required for growth and proliferation of SHF progenitor cells, in part by regulating the expression of *Rspo3* and by modulation of Wnt signaling. Identification of *Rspo3*, a potent Wnt agonist, as a target of *Nkx2-5* in the developing heart, has significant implication for the growth and development of the embryonic heart. Whereas R-spondins are shown to synergize with *Wnt3a* to activate canonical Wnt signaling (our data; Nam et al., 2006; Kazanskaya et al., 2008; Baljinnyam et al., 2012), recent studies also provide strong evidence for the activation of the non-canonical Wnt pathway by *Rspo3* (Ohkawara et al., 2011; Glinka et al., 2011). Multiple independent studies have now shown that stem cell markers and orphan receptors, *Lgr5* and *Lgr4*, bind R-spondins and activate both canonical and non-canonical Wnt signaling pathways (Carmon et al., 2011; de Lau




Fig. 9. Pharmacological rescue of SHF defects in conditional *Nkx2-5* mutants. Pregnant females were treated with intraperitoneal injections of LiCl or NaCl from E8-E10 of gestation. (A-C) All *Nkx2-5* conditional mutants treated with NaCl had a single OFT (PTA) at E17.5 ($n=12$). (D-G) 67% ($n=10/15$; $P=0.01$) of the conditional *Rspo3* mutants (E-G) treated with LiCl had a significantly larger RV (arrows) and showed OFT septation. Treatment with LiCl did not correct the OFT alignment defects in the mutants (E). In A, D, E, aorta and pulmonary artery are indicated by arrows. Ao, aorta; LV, left ventricle; OFT, outflow tract; Pa, pulmonary artery; PTA, persistent truncus arteriosus; RV, right ventricle.

et al., 2011; Glinka et al., 2011). Given the well-studied role of Wnt/ β -catenin signaling in growth and development of SHF, it is plausible that *Rspo3* potentiates this process and thus promotes progenitor cell proliferation.

Supporting the notion that Wnt signaling is a positive regulator of cardiomyocyte proliferation is the finding that conditional loss of β -catenin in cardiac progenitors resulted in diminished myocardial growth and hypoplasia of both cardiac fields (Kwon et al., 2008). Furthermore, heterozygous loss of β -catenin was sufficient to suppress the cardiomyocyte overgrowth in the Hippo pathway mutants, suggesting a crucial link between canonical Wnt pathway and myocardial proliferation (Heallen et al., 2011). Therefore, it is plausible that potentiation of Wnt signaling by *Rspo3* is crucial for cardiac growth and development. Whether *Rspo3* functions in the cardiomyocytes, endocardial cells, or both, is currently being investigated. *Isl1Cre* operates in the majority of cardiac myocytes and in only a subset of endocardial cells (Yang et al., 2006; Milgrom-Hoffman et al., 2011). In this regard, we consistently observe a diminished number of endocardial cells in *Rspo3* mutants. Therefore, it would be important to test whether *Rspo3* from myocardium can attenuate cell growth or survival in endocardium.

In line with our hypothesis, we were able to rescue the majority of SHF defects in the *Nkx2-5* mutants by activation of Wnt signaling, suggesting that *Nkx2-5* serves cell-autonomous and non-cell-autonomous functions in the SHF. The molecular link between *Nkx2-5* and Wnt signaling was suggested by a recent study (Klaus et al., 2012), thus providing further evidence for transcriptional attenuation of specific signaling pathways. Pharmacological rescue of OFT septation in the *Nkx2-5* mutants provides strong evidence that *Nkx2-5* and canonical Wnt signaling overlap significantly in genetic pathways leading to cardiogenesis. The attenuation of Wnt signaling by *Nkx2-5* may have implication in the temporal aspect of cell division and differentiation of SHF progenitors.

A recent study suggested that Wnt and Bmp signals control distinct sets of transcription factors in cardiac progenitors of SHF (Klaus et al., 2012). Our data are in line with these observations, as *Rspo3* was able to rescue the SHF defects in the *Nkx2-5* mutants, thus providing strong evidence for the genetic interaction of *Nkx2-5* and the Wnt pathway. Prior studies have shown that excess activation of the Wnt pathway by a constitutively active β -catenin results in early embryonic lethality (Kwon et al., 2007; Grigoryan et al., 2008). We similarly observed that conditional overexpression

of *Rspo3* in the precardiac/cardiac mesoderm results in excess activation of β -catenin and embryonic lethality. Surprisingly, we find that the only surviving *Rspo3*^{OE} mutants are on the *Nkx2-5* mutant background, thus providing an independent line of evidence that loss of *Nkx2-5* can attenuate excess Wnt signal by *Rspo3*. Therefore, our studies point to the previously unrecognized genetic interaction of *Nkx2-5* and Wnt signaling in the development of SHF.

MATERIALS AND METHODS

Mice

All mouse lines have been described previously: *Rspo3*-floxed allele (Kazanskaya et al., 2008); *Nkx2-5*-floxed allele (Pashmforoush et al., 2004), *Mef2cCre* (Dodou et al., 2004), *Isl1Cre* (Cai et al., 2003), *Bmp2*-floxed allele (Rivera-Feliciano and Tabin, 2006), *Foxa2Cre*^{mc/m} (Park et al., 2008), TOPGAL (DasGupta and Fuchs, 1999) and BATGAL (Maretto et al., 2003). All mouse lines were of mixed C57BL6/129SVEJ background. The embryos were collected at E8.5 to neonatal stage. Transgenic mice carrying the *Rspo3* overexpression transgene were generated at the transgenic facility of the University of California, Irvine. Ten founder mice were initially determined by PCR analysis of tail DNA. Subsequently, the lines expressing high levels of chloramphenicol acetyl transferase (CAT) were identified by a colorimetric assay of CAT enzyme isolated from tail tissue. The transgenic mice were crossed into the *Nkx2-5*-floxed allele for at least six generations. For *in vivo* pharmacological rescues, pregnant mice were injected interperitoneally with 200 mg/kg LiCl once a day at the indicated times. Tamoxifen-induced gene knockout is described in the Methods in the supplementary material. All animal procedures were performed in accordance with the Institute for Animal Care and Use Committee at the University of Southern California.

Constructs

Rspo3 enhancer constructs for transient transgenic experiments and luciferase assays were created by PCR amplification using high-fidelity Taq polymerase using primers that span the *Rspo3* promoter region and site 3. The PCR fragments were cloned into pGH-*lacZ*, which contains the *HSP68* core promoter upstream of *lacZ* coding sequences as previously described (Creemers et al., 2006). For luciferase assays the PCR fragments were cloned into pGL3 (Promega). Constructs were verified by sequencing.

Histology and immunofluorescence

Embryos were isolated and fixed in 4% PFA/PBS overnight and then dehydrated and embedded in OCT (Sakura Finetek). Sections of 10 μ m thickness were collected on slides and subjected to immunostaining. The primary antibodies were PY489- β -catenin (DHSB, Balsamo; 1/100),




Fig. 10. *In vivo* expression of *Rspo3* rescues the SHF defects in conditional *Nkx2-5* mutants. (A) Transgene construct for the conditional *Rspo3* expression, in which a chloramphenicol acetyl transferase *loxP* (CAT)-STOP *loxP*-*Rspo3* gene cassette is driven by CMV/chicken β-actin promoter. (B) Western blot showing a significant increase in active β-catenin in embryonic hearts (E10.5) isolated from *Rspo3^{OE}* transgenic mice crossed with *Isl1-ires-Cre* line. (C) The majority of embryos carrying the Cre-activated *Rspo3^{OE}* transgene die *in utero*. By contrast, most of *Rspo3*-overexpressing mice on the *Nkx2-5* mutant background are recovered at birth. (D-L) Whole-mount and H&E stain of sections from control and rescued *Nkx2-5* conditional mutants. Conditional activation of *Rspo3* on the *Nkx2-5* mutant background results in the rescue of RV/OFT defects (F,I,L) compared with the simple mutants (E,H,K), and is comparable to the control neonates (D,G,J). The ventricular septal defect is absent in the rescued heart and RV size appears larger (white arrows). Black arrows represent aorta and pulmonary artery in D,F,I and PTA in E,H, PA, pulmonary artery.

Nkx2-5 (Santa Cruz Biotechnology, Sc-8697; 1/100), *Pecam1* (BD Pharmingen, 550274; 1/100), *Isl1* (DSHB, 40.3A4; 1/100), α-actinin (Sigma, A7811; 1/1000); and *Rspo3* (R&D Systems, MAB 41201; 1/50).

In situ hybridization

Whole-mount and section *in situ* hybridization were performed according to previously described protocols (Moormann et al., 2001). Briefly, the fixed embryos were digested with proteinase K to facilitate probe penetration. After washes, the embryos were incubated with digoxigenin-labeled antisense RNA (Roche) at 70°C overnight. After several high-stringency washes post-hybridization, embryos were blocked for 2 hours at room temperature, followed by incubation with alkaline phosphatase-conjugated anti-digoxigenin antibody (Roche). After extensive washes embryos were incubated with BM Purple (Roche) for colorimetric detection of labeled transcript.

β-galactosidase staining

Embryos from timed pregnancies were isolated and fixed for 30 min in 4% PFA/PBS at 4°C. β-galactosidase staining was performed as described (Yamagishi et al., 2003). Sections were counterstained by nuclear Fast Red.

Electrophoretic mobility shift assay (EMSA)

Experiments were performed using annealed double-stranded oligonucleotides derived from the indicated region (site 3) of the *Rspo3* promoter and recombinant *Nkx2-5* protein. Briefly, wild-type double-stranded oligonucleotides for the *Nkx2-5* binding sequence from the *Rspo3* promoter region, *Nkx2-5*-2214WT: 5'-CCAGCTCAAGTAGCCTGGAT-TAGA-3' and *Nkx2-5*-2214Mut: CCGCTCCCTCAGCCTGGATTAGA, were synthesized, and the two complementary oligonucleotides were annealed and labeled with [α-³²P]-dATP and [α-³²P]-dCTP using the Klenow enzyme. The labeled probes were incubated with 10 μl of *in vitro*-translated protein

product and binding buffer containing 0.25 mg/ml poly dI-dC for 30 min at room temperature. For the super gel shift, 1 μl of *Nkx2-5* (N-19) was added and kept at room temperature for 30 min longer. For the competition reaction, 200-fold excess of unlabeled wild-type probe was added. The protein/DNA mixture was resolved on a 6% polyacrylamide gel.

ESC culture and EBs

Murine ESCs were propagated undifferentiated on mytomycin-C-treated MEFs in maintenance medium of Glasgow MEM (Sigma; G5154) supplemented with 10% FBS (HyClone; SH30071.03), 1 mM 2-mercaptoethanol (Sigma; M7522), 2 mM L-glutamine (Gibco-BRL; 25030-081), 1 mM sodium pyruvate (GIBCO-BRL; 11360-070), 0.1 mM nonessential amino acids and 1000 units/ml leukemia inhibitory factor (LIF) (Chemicon International; ESG1107). All ESC manipulations and formation of EBs were carried out according to Kwon et al. (2007). EBs were formed by the hanging drop method in differentiation medium (DM) that contained the same components as the maintenance medium but with 20% FBS added and without LIF. For treatment, the medium was replaced with DM containing Wnt3a (150 ng/ml, R&D Systems) or *Rspo3* (150-200 ng/ml, R&D Systems) at the start of day 3. On day 5, the medium was replaced with fresh DM. Protein and RNA were isolated from EBs on days 5 and 6 of differentiation, respectively (Kwon et al., 2007).

In vivo ChIP assays

Whole heart was extracted from wild-type E10.5 embryos and processed as detailed in the Methods in the supplementary material. Chromatin was immunoprecipitated with either the *Nkx2-5* (N-19; Santa Cruz Biotechnology) or a normal goat IgG control antibody. Amplified fragments were analyzed on a 1.5% agarose gel or qPCR was performed using a DNA Engine Oton2 thermal cycler (MJ Research) with SYBR Green Supermix (Bio-Rad) and quantitative differences were determined. Each ChIP assay was performed at least three times, and qPCR results represent the mean±s.e.m. of

three assays. ChIP assay primers are detailed in the Methods in the supplementary material.

Quantitative RT-PCR (qRT-PCR)

Total RNA was isolated from E9.5 or 10.5 hearts with Trizol reagent (Invitrogen) and 1 µg was reverse transcribed using the iScript cDNA Synthesis Kit (Bio-Rad). Real-time PCR reactions were performed using the iQTM SYBR Green Supermix (Bio-Rad). The qPCR data were normalized to the expression of β-actin or *Gapdh* (primers are listed in supplementary material Table S1). Statistical analyses were performed using Student's *t*-test. The results are the average of three or more independent experiments in triplicate.

Promoter cloning and luciferase reporter assays

The 3 kb genomic DNA fragment containing the putative Nkx2-5 binding site upstream of the *Rspo3* (ENSMUSG00000019880) start codon, and 290 bp and 460 bp fragments were amplified as described in the Methods in the supplementary material. The luciferase transfection assay was performed in 293T cells as described in the Methods in the supplementary material.

Acknowledgements

We thank Mr and Mrs Paul Simon for their generosity. We are grateful for the support of the California Institute for Regenerative Medicine (CIRM).

Competing interests

The authors declare no competing financial interests.

Author contributions

L.C. and M. Pashmforoush developed the concepts and approach, analyzed the data for these studies and wrote the manuscript. L.C. performed most of the experiments with help from M. Plate. H.M.S. participated in developing the study concept and editing the manuscript.

Funding

This work was supported by CIRM grant RN1-00562. The authors were also supported by generous gifts from the Simon-Strauss Foundation. H.M.S. was funded by the National Institutes of Health [HL070123]. Deposited in PMC for release after 12 months.

Supplementary material

Supplementary material available online at <http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.103416/-DC1>

References

- Ai, D., Fu, X., Wang, J., Lu, M. F., Chen, L., Baldini, A., Klein, W. H. and Martin, J. F. (2007). Canonical Wnt signaling functions in second heart field to promote right ventricular growth. *Proc. Natl. Acad. Sci. USA* **104**, 9319-9324.
- Altschul, S. F., Gish, W., Miller, W., Myers, E. W. and Lipman, D. J. (1990). Basic local alignment search tool. *J. Mol. Biol.* **215**, 403-410.
- Aoki, M., Mieda, M., Ikeda, T., Hamada, Y., Nakamura, H. and Okamoto, H. (2007). R-spondin3 is required for mouse placental development. *Dev. Biol.* **301**, 218-226.
- Baljinnyam, B., Klauzinska, M., Saffo, S., Callahan, R. and Rubin, J. S. (2012). Recombinant R-spondin2 and Wnt3a up- and down-regulate novel target genes in C57MG mouse mammary epithelial cells. *PLoS ONE* **7**, e29455.
- Bibens, C. and Harvey, R. P. (1997). Homeodomain factor Nkx2-5 controls left/right asymmetric expression of bHLH gene eHand during murine heart development. *Genes Dev.* **11**, 1357-1369.
- Biechele, T. L., Adams, A. M. and Moon, R. T. (2009). Transcription-based reporters of Wnt/beta-catenin signaling. *Cold Spring Harb. Protoc.* **2009**, pdb. prot5223.
- Brown, C. B., Feiner, L., Lu, M. M., Li, J., Ma, X., Webber, A. L., Jia, L., Raper, J. A. and Epstein, J. A. (2001). PlexinA2 and semaphorin signaling during cardiac neural crest development. *Development* **128**, 3071-3080.
- Buckingham, M., Meilhac, S. and Zaffran, S. (2005). Building the mammalian heart from two sources of myocardial cells. *Nat. Rev. Genet.* **6**, 826-837.
- Cai, C.-L., Liang, X., Shi, Y., Chu, P.-H., Pfaff, S. L., Chen, J. and Evans, S. (2003). Isl1 identifies a cardiac progenitor population that proliferates prior to differentiation and contributes a majority of cells to the heart. *Dev. Cell* **5**, 877-889.
- Carmon, K. S., Gong, X., Lin, Q., Thomas, A. and Liu, Q. (2011). R-spondins function as ligands of the orphan receptors LGR4 and LGR5 to regulate Wnt/beta-catenin signaling. *Proc. Natl. Acad. Sci. USA* **108**, 11452-11457.
- Creemers, E. E., Sutherland, L. B., McAnally, J., Richardson, J. A. and Olson, E. N. (2006). Myocardin is a direct transcriptional target of Mef2, Tead and Foxo proteins during cardiovascular development. *Development* **133**, 4245-4256.
- Cohen, E. D., Wang, Z., Lepore, J. J., Lu, M. M., Taketo, M. M., Epstein, D. J. and Morrisey, E. E. (2007). Wnt/beta-catenin signaling promotes expansion of Isl-1-positive cardiac progenitor cells through regulation of FGF signaling. *J. Clin. Invest.* **117**, 1794-1804.
- DasGupta, R. and Fuchs, E. (1999). Multiple roles for activated LEF/TCF transcription complexes during hair follicle development and differentiation. *Development* **126**, 4557-4568.
- de Lau, W., Barker, N., Low, T. Y., Koo, B.-K., Li, V. S. W., Teunissen, H., Kujala, P., Haegebarth, A., Peters, P. J., van de Wetering, M. et al. (2011). Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling. *Nature* **476**, 293-297.
- Dodou, E., Verzi, M. P., Anderson, J. P., Xu, S.-M. and Black, B. L. (2004). Mef2c is a direct transcriptional target of ISL1 and GATA factors in the anterior heart field during mouse embryonic development. *Development* **131**, 3931-3942.
- Feiner, L., Webber, A. L., Brown, C. B., Lu, M. M., Jia, L., Feinstein, P., Mombaerts, P., Epstein, J. A. and Raper, J. A. (2001). Targeted disruption of semaphorin 3C leads to persistent truncus arteriosus and aortic arch interruption. *Development* **128**, 3061-3070.
- Glinka, A., Dolde, C., Kirsch, N., Huang, Y.-L., Kazanskaya, O., Ingelfinger, D., Boutros, M., Cruciat, C.-M. and Niehrs, C. (2011). LGR4 and LGR5 are R-spondin receptors mediating Wnt/beta-catenin and Wnt/PCP signalling. *EMBO Rep.* **12**, 1055-1061.
- Grigoryan, T., Wend, P., Klaus, A. and Birchmeier, W. (2008). Deciphering the function of canonical Wnt signals in development and disease: conditional loss- and gain-of-function mutations of beta-catenin in mice. *Genes Dev.* **22**, 2308-2341.
- Habets, P. E. M. H., Moorman, A. F. M., Clout, D. E. W., van Roon, M. A., Lingbeek, M., van Lohuizen, M., Campione, M. and Christoffels, V. M. (2002). Cooperative action of Tbx2 and Nkx2.5 inhibits ANF expression in the atrioventricular canal: implications for cardiac chamber formation. *Genes Dev.* **16**, 1234-1246.
- Heallen, T., Zhang, M., Wang, J., Bonilla-Claudio, M., Klysiak, E., Johnson, R. L. and Martin, J. F. (2011). Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. *Science* **332**, 458-461.
- Jay, P. Y., Harris, B. S., Maguire, C. T., Buerger, A., Wakimoto, H., Tanaka, M., Kupersmidt, S., Roden, D. M., Schultheiss, T. M., O'Brien, T. X. et al. (2004). Nkx2-5 mutation causes anatomic hypoplasia of the cardiac conduction system. *J. Clin. Invest.* **113**, 1130-1137.
- Jiang, X., Rowitch, D. H., Soriano, P., McMahon, A. P., Sucov, H. M. et al. (2000). Fate of the mammalian cardiac neural crest. *Development* **127**, 1607-1616.
- Kazanskaya, O., Glinka, A., del Barco Barrantes, I., Stanek, P., Niehrs, C. and Wu, W. (2004). R-Spondin2 is a secreted activator of Wnt/beta-catenin signaling and is required for *Xenopus* myogenesis. *Dev. Cell* **7**, 525-534.
- Kazanskaya, O., Ohkawara, B., Heroult, M., Wu, W., Maltry, N., Augustin, H. G. and Niehrs, C. (2008). The Wnt signaling regulator R-spondin 3 promotes angioblast and vascular development. *Development* **135**, 3655-3664.
- Kirby, M. L. and Waldo, K. L. (1995). Neural crest and cardiovascular patterning. *Circ. Res.* **77**, 211-215.
- Kirby, M. L., Turnage, K. L., III and Hays, B. M. (1985). Characterization of conotruncal malformations following ablation of "cardiac" neural crest. *Anat. Rec.* **213**, 87-93.
- Klaus, A., Saga, Y., Taketo, M. M., Tzahor, E. and Birchmeier, W. (2007). Distinct roles of Wnt/beta-catenin and Bmp signaling during early cardiogenesis. *Proc. Natl. Acad. Sci. USA* **104**, 18531-18536.
- Klaus, A., Müller, M., Schulz, H., Saga, Y., Martin, J. F. and Birchmeier, W. (2012). Wnt/beta-catenin and Bmp signals control distinct sets of transcription factors in cardiac progenitor cells. *Proc. Natl. Acad. Sci. USA* **109**, 10921-10926.
- Klein, P. S. and Melton, D. A. (1996). A molecular mechanism for the effect of lithium on development. *Proc. Natl. Acad. Sci. USA* **93**, 8455-8459.
- Kothary, R., Clapoff, S., Darling, S., Perry, M. D., Moran, L. A. and Rossant, J. (1989). Inducible expression of an hsp68-lacZ hybrid gene in transgenic mice. *Development* **105**, 707-714.
- Kwon, C., Arnold, J., Hsiao, E. C., Taketo, M. M., Conklin, B. R. and Srivastava, D. (2007). Canonical Wnt signaling is a positive regulator of mammalian cardiac progenitors. *Proc. Natl. Acad. Sci. USA* **104**, 10894-10899.
- Kwon, C., Cordes, K. R. and Srivastava, D. (2008). Wnt/beta-catenin signaling acts at multiple developmental stages to promote mammalian cardiogenesis. *Cell Cycle* **7**, 3815-3818.
- Lin, L., Cui, L., Zhou, W., Dufort, D., Zhang, X., Cai, C.-L., Bu, L., Yang, L., Martin, J., Kemler, R. et al. (2007). Beta-catenin directly regulates Islet1 expression in cardiovascular progenitors and is required for multiple aspects of cardiogenesis. *Proc. Natl. Acad. Sci. USA* **104**, 9313-9318.
- Lyons, I., Parsons, L. M., Hartley, L., Li, R., Andrews, J. E., Robb, L. and Harvey, R. P. (1995). Myogenic and morphogenetic defects in the heart tubes of murine embryos lacking the homeo box gene Nkx2-5. *Genes Dev.* **9**, 1654-1666.
- Maretto, S., Cordenonsi, M., Dupont, S., Braghetta, P., Broccoli, V., Hassan, A. B., Volpin, D., Bressan, G. M. and Piccolo, S. (2003). Mapping Wnt/beta-catenin

- signaling during mouse development and in colorectal tumors. *Proc. Natl. Acad. Sci. USA* **100**, 3299-3304.
- Mayor, C., Brudno, M., Schwartz, J. R., Poliakov, A., Rubin, E. M., Frazer, K. A., Pachter, L. S. and Dubchak, I. (2000). VISTA: visualizing global DNA sequence alignments of arbitrary length. *Bioinformatics* **16**, 1046-1047.
- Milgrom-Hoffman, M., Harrelson, Z., Ferrara, N., Zelzer, E., Evans, S. M. and Tzahor, E. (2011). The heart endocardium is derived from vascular endothelial progenitors. *Development* **138**, 4777-4787.
- Moorman, A. F., Houweling, A. C., de Boer, P. A. J. and Christoffels, V. M. (2001). Sensitive nonradioactive detection of mRNA in tissue sections: novel application of the whole-mount in situ hybridization protocol. *J. Histochem. Cytochem.* **49**, 1-8.
- Nakamura, T., Sano, M., Songyang, Z. and Schneider, M. D. (2003). A Wnt- and beta-catenin-dependent pathway for mammalian cardiac myogenesis. *Proc. Natl. Acad. Sci. USA* **100**, 5834-5839.
- Nakashima, Y., Ono, K., Yoshida, Y., Kojima, Y., Kita, T., Tanaka, M. and Kimura, T. (2009). The search for Nkx2-5-regulated genes using purified embryonic stem cell-derived cardiomyocytes with Nkx2-5 gene targeting. *Biochem. Biophys. Res. Commun.* **390**, 821-826.
- Nam, J.-S., Turcotte, T. J., Smith, P. F., Choi, S. and Yoon, J. K. (2006). Mouse cristin/R-spondin family proteins are novel ligands for the Frizzled 8 and LRP6 receptors and activate beta-catenin-dependent gene expression. *J. Biol. Chem.* **281**, 13247-13257.
- Nam, J.-S., Turcotte, T. J. and Yoon, J. K. (2007). Dynamic expression of R-spondin family genes in mouse development. *Gene Expr. Patterns* **7**, 306-312.
- Ohkawara, B., Glinka, A. and Niehrs, C. (2011). Rspo3 binds syndecan 4 and induces Wnt/PCP signaling via clathrin-mediated endocytosis to promote morphogenesis. *Dev. Cell* **20**, 303-314.
- Park, E. J., Sun, X., Nichol, P., Saijoh, Y., Martin, J. F. and Moon, A. M. (2008). System for tamoxifen-inducible expression of cre-recombinase from the Foxa2 locus in mice. *Dev. Dyn.* **237**, 447-453.
- Pashmforoush, M., Lu, J. T., Chen, H., Amand, T. S., Kondo, R., Pradervand, S., Evans, S. M., Clark, B., Feramisco, J. R., Giles, W. et al. (2004). Nkx2-5 pathways and congenital heart disease; loss of ventricular myocyte lineage specification leads to progressive cardiomyopathy and complete heart block. *Cell* **117**, 373-386.
- Prall, O. W. J., Menon, M. K., Solloway, M. J., Watanabe, Y., Zaffran, S., Bajolle, F., Biben, C., McBride, J. J., Robertson, B. R., Chaulet, H. et al. (2007). An Nkx2-5/Bmp2/Smad1 negative feedback loop controls heart progenitor specification and proliferation. *Cell* **128**, 947-959.
- Qyang, Y., Martin-Puig, S., Chiravuri, M., Chen, S., Xu, H., Bu, L., Jiang, X., Lin, L., Granger, A., Moretti, A. et al. (2007). The renewal and differentiation of Isl1+ cardiovascular progenitors are controlled by a Wnt/beta-catenin pathway. *Cell Stem Cell* **1**, 165-179.
- Rhee, J., Buchan, T., Zukerberg, L., Lilien, J. and Balsamo, J. (2007). Cables links Robo-bound Abl kinase to N-cadherin-bound beta-catenin to mediate Slit-induced modulation of adhesion and transcription. *Nat. Cell Biol.* **9**, 883-892.
- Rivera-Feliciano, J. and Tabin, C. J. (2006). Bmp2 instructs cardiac progenitors to form the heart-valve-inducing field. *Dev. Biol.* **295**, 580-588.
- Schleiffarth, J. R., Person, A. D., Martinsen, B. J., Sukovich, D. J., Neumann, A., Baker, C. V., Lohr, J. L., Cornfield, D. N., Ekker, S. C. and Petryk, A. (2007). Wnt5a is required for cardiac outflow tract septation in mice. *Pediatr. Res.* **61**, 386-391.
- Schneider, V. A. and Mercola, M. (2001). Wnt antagonism initiates cardiogenesis in *Xenopus laevis*. *Genes Dev.* **15**, 304-315.
- Song, L., Li, Y., Wang, K. and Zhou, C. J. (2010). Cardiac neural crest and outflow tract defects in Lrp6 mutant mice. *Dev. Dyn.* **239**, 200-210.
- Srinivas, S., Watanabe, T., Lin, C.-S., Williams, C. M., Tanabe, Y., Jessell, T. M. and Costantini, F. (2001). Cre reporter strains produced by targeted insertion of EYFP and ECFP in the ROSA26 locus. *BMC Dev. Biol.* **1**, 4.
- Sun, Y., Liang, X., Najafi, N., Cass, M., Lin, L., Cai, C.-L., Chen, J. and Evans, S. M. (2007). Islet 1 is expressed in distinct cardiovascular lineages, including pacemaker and coronary vascular cells. *Dev. Biol.* **304**, 286-296.
- Tanaka, M., Chen, Z., Bartunkova, S., Yamasaki, N. and Izumo, S. (1999). The cardiac homeobox gene Csx/Nkx2.5 lies genetically upstream of multiple genes essential for heart development. *Development* **126**, 1269-1280.
- Tian, Y., Yuan, L., Goss, A. M., Wang, T., Yang, J., Lepore, J. J., Zhou, D., Schwartz, R. J., Patel, V., Cohen, E. D. et al. (2010). Characterization and in vivo pharmacological rescue of a Wnt2-Gata6 pathway required for cardiac inflow tract development. *Dev. Cell* **18**, 275-287.
- Ueno, S., Weidinger, G., Osugi, T., Kohn, A. D., Golob, J. L., Pabon, L., Reinecke, H., Moon, R. T. and Murry, C. E. (2007). Biphasic role for Wnt/beta-catenin signaling in cardiac specification in zebrafish and embryonic stem cells. *Proc. Natl. Acad. Sci. USA* **104**, 9685-9690.
- Verzi, M. P., McCulley, D. J., De Val, S., Dodou, E. and Black, B. L. (2005). The right ventricle, outflow tract, and ventricular septum comprise a restricted expression domain within the secondary/anterior heart field. *Dev. Biol.* **287**, 134-145.
- Waldo, K. L., Kumiski, D. H., Wallis, K. T., Stadt, H. A., Hutson, M. R., Platt, D. H. and Kirby, M. L. (2001). Conotruncal myocardium arises from a secondary heart field. *Development* **128**, 3179-3188.
- Wang, J., Li, S., Chen, Y. and Ding, X. (2007). Wnt/beta-catenin signaling controls Mesp2 expression to regulate segmentation during *Xenopus* somitogenesis. *Dev. Biol.* **304**, 836-847.
- Wu, X., Golden, K. and Bodmer, R. (1995). Heart development in *Drosophila* requires the segment polarity gene wingless. *Dev. Biol.* **169**, 619-628.
- Yamagishi, H., Maeda, J., Hu, T., McAnally, J., Conway, S. J., Kume, T., Meyers, E. N., Yamagishi, C. and Srivastava, D. (2003). Tbx1 is regulated by tissue-specific forkhead proteins through a common Sonic hedgehog-responsive enhancer. *Genes Dev.* **17**, 269-281.
- Yang, L., Cai, C.-L., Lin, L., Qyang, Y., Chung, C., Monteiro, R. M., Mummery, C. L., Fishman, G. I., Cogen, A. and Evans, S. (2006). Isl1Cre reveals a common Bmp pathway in heart and limb development. *Development* **133**, 1575-1585.
- Zaffran, S., Kelly, R. G., Meilhac, S. M., Buckingham, M. E. and Brown, N. A. (2004). Right ventricular myocardium derives from the anterior heart field. *Circ. Res.* **95**, 261-268.
- Zaffran, S., Reim, I., Qian, L., Lo, P. C., Bodmer, R. and Frasch, M. (2006). Cardioblast-intrinsic Tinman activity controls proper diversification and differentiation of myocardial cells in *Drosophila*. *Development* **133**, 4073-4083.
- Zhou, W., Lin, L., Majumdar, A., Li, X., Zhang, X., Liu, W., Etheridge, L., Shi, Y., Martin, J., Van de Ven, W. et al. (2007). Modulation of morphogenesis by noncanonical Wnt signaling requires ATF/CREB family-mediated transcriptional activation of TGFbeta2. *Nat. Genet.* **39**, 1225-1234.

Supplementary Methods

Tamoxifen-induced gene knockout

Foxa2^{Cre/Es1} pregnant females were treated with a single interaperitoneal injection of tamoxifen (100 mg/kg; Sigma, T5648) dissolved in corn oil at E6.5-7 as described previously (Park et al., 2008).

In vivo CHIP assays

Whole heart was extracted from wild-type E10.5 embryos and chopped into small pieces using two razor blades; 1 ml nuclei extraction buffer [0.5% Triton X-100, 10 mM Tris-HCl (pH 7.5), 3 mM CaCl₂, 0.25 M sucrose, protease inhibitor (one tablet/10 ml), 1 mM DTT, 0.2 mM PMSF] was added and then the tissue was transferred to 1.7 ml tubes, 25 µl 37% formaldehyde was added, and rotated at room temperature for 15 min followed by addition of 100 µl 1 M Tris-HCl (pH 9.5) and rotation for another 5 min. The sediment was centrifuged at 2000 *g* at 4° C for 2 min and the pellet transferred into 1 ml nuclei extraction buffer and homogenized with 5-10 strokes. The pellet was then filtered through a Falcon 100 µm cell strainer and recentrifuged. 200-300 µl SDS lysis buffer was added to the resuspended pellet. Sonication, immunoprecipitation and elution were carried out using a CHIP Assay Kit (Upstate).

ChiP assay primers:

SITE 1-F: GCA TTA CAA AAG AAT CCT TCA
SITE 1-R: TAA ACC ACT ACC AGG GAA AA

SITE 2-F: GTG CTT TTC AAT GAG ACA GG
SITE 2-R: CAA GCC TCA AAG CAT TTT TA

SITE 3-F: GTG CTC ATT TCC CTG AAC T
SITE 3-R: CAG CTT TTT GTT CCT TCT TG

SITE 4-F: TGG ATC AAG AAC CTT AGC TG
SITE 4-R: CTT GAG CTG GAT AGG ATG AG

SITE 5-F: CCA TTC CTG TTC TCA TCC TA
SITE 5-R: GAA TAT CGG CAT CAT CAA CT


SITE 6-F: CCC ATA ACT TCA TAG AGA AGG A
SITE 6-R: ATG GAG TCT AAC CAC CCT TT

Promoter cloning and luciferase reporter assays

The 3 kb genomic DNA fragment containing the putative Nkx2-5 binding site upstream of the *Rspo3* (ENSMUSG00000019880) start codon, and 290 bp (forward 5'-AGATGCCACCCCAATTCCAA-3' and reverse 5'-GGTGTCCGTCATTGTGCTCA-3') and


460 bp (forward 5'-AGATGCCACCCAATTCCAA-3' and reverse 5'-TGAATGGTGCTTGTTCCCTTG-3') fragments were amplified with Phusion high-fidelity DNA polymerase (New England BioLabs, F-530S/L) and cloned into the pGL3-basic vector (Promega, E1751).

For the luciferase transfection assay, we transfected 293T cells with Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Unless otherwise indicated, 100 ng reporter and 100 ng of each plasmid were used; 10 ng CMV-*Renilla* luciferase was used as an internal control to normalize for variations in transfection efficiency. Luciferase assays were performed using a Dual Luciferase Reporter Assay System (Promega), and reported values are the mean \pm s.e.m. of three assays performed in duplicate.




Suppl. Fig. 1. Conditional mutants of Nkx2-5 by Isl1-Cre and Mef2c-Cre.

(A-C) Lineage analysis of Isl1Cre (Yang et al., 2006) line crossed with R26R-lacZ reporter line showing efficient recombination in descendants of SHF that give rise to RV and OFT, and a large number of cells in the LV at E10.5 (A,B) and E13.5 (C). (D,E) Comparison of heterozygous (Isl1^{Cre}/Nkx2-5^{f/wt}) and mutant (Isl1^{Cre}/Nkx2-5^{f/f}) embryos at E9.5, showing poorly developed RV and OFT. (F-H) Comparisons of heart development in the conditional heterozygote (F), conditional mutant (G), and the conventional Nkx2-5 mutant (H) at E9.5. Compared to the conventional Nkx2-5 mutants, the OFT is better developed in the conditional mutants. (I,J,L,M) Whole-mount X-gal analysis of the heterozygote (Mef2cCre/Nkx2-5^{f/wt}) and mutant (Mef2cCre/Nkx2-5^{f/f}) hearts shown in R26R-lacZ background at E9.5. The right ventricle is virtually absent in the Nkx2-5 mutant embryos, while OFT myocardium is still present. (K,N) In situ hybridization using Mlc2v probe showing properly differentiated myocardium in the conditional Nkx2-5 mutants.




Suppl. Fig. 2. Efficiency of *Isl1-Ires-Cre* recombination in the *Nkx2-5* mutants.

(A-D) Immunofluorescence stain using *Nkx2-5* antibody shows prominent loss of *Nkx2-5* in the RV of the mutants but not in the LV. (E,F) Immunohistochemical staining for *Nkx2-5* showing marked loss of *Nkx2-5* in the RV and OFT. *Nkx2-5*-positive nuclei are uniformly present in the heterozygous RV.




Suppl. Fig.3. Loss of Bmp2 does not rescue conditional Nkx2-5 mutants.

In situ hybridization for Bmp2 (A-D) and Bmp4 (E,F) showing comparable expression in the control and mutant OFTs. (G-J) H&E staining of E14.5 Bmp2 and compound heterozygous (G,I) and compound mutants (H,J) sections showing the presence of PTA and VSD in the compound mutants of Nkx2-5 and Bmp2.




Suppl. Fig. 4. Loss of Nkx2-5 in the pharyngeal endoderm does not affect OFT septation.

(A,B) In situ hybridization showing expression of Shh in the endoderm-specific conditional Nkx2-5 mutants. (C,D) Endoderm-specific ablation of Nkx2-5 using *Foxa2^{Cre/Esr1}* does not result in OFT septation or alignment defects.




Suppl. Fig .5. Quantitative RT-PCR analysis of selective Wnt genes in the Nkx2-5 mutants.

RNA isolated from SHF (RV/OFT) of Nkx2-5 mutants and controls at E10.5 was subjected to qPCR analysis. Only Wnt2 showing a modest decrease in the conditional Nkx2-5 mutants, but examination of other Wnt ligands showed either undetectable or insignificant changes as analyzed by qPCR.



Suppl. Fig. 6. Expression of Rspo3 in the E14.5 mouse embryo.

(A,B) In situ hybridization showing Rspo3 expression in the heart becomes restricted to the valvular apparatus and myocardium of the inflow and the outflow tract (adapted from: eurexpress.org).



Suppl. Fig. 7. Conditional loss of *Rspo3* by *Isl1*-ires-Cre results in SHF defects.

(A-F) Inactivation of *Rspo3* results in embryonic (E13.5) heart failure with resultant pericardial edema, DORV (B), and a significantly smaller RV (D,F).

Table S1. Primers used for RT-PCR and qPCR reactions

Gene name(s)	Forward primer	Reverse primer
<i>Actb</i>	GCTGTATTCCCCTCCATC	GGGTGTTGAAGGTCTCAA
<i>Angiopoietin 1</i>	AGCTGACAGATGTTGAGACC	TGATGAATGTCTGACGAGAA
<i>Bmp2</i>	GAGATGAGTGGGAAAACG	GCAGTAAAGGCATGATAGC
<i>Bmp4</i>	AAGTTTCCCACCGTGTCATT	CCGAGCCAACACTGTGAGGAGT
<i>Fgf10</i>	ACATTGTGCCTCAGCCTTTC	TTCCATTCAATGCCACATACAT
<i>Gapdh</i>	CATGGCCTTCCGTGTTCTTA	CCTGCTTCACCACCTTCTTGAT
<i>Hod</i>	TGGAGTACAACCTCAACAAGG	TGTGTTAAATAGCAGGACAGC
<i>Pdgfra</i>	AGATAGCTTCATGAGCCGAC	GGAACAGGGTCAATGTCTGG
<i>Rspo3</i>	GTGTTTCAAGATTACAATGGCT	CCCTTTTGAAGCCACATGTTT
<i>Sema3C</i>	CCACCCGAAGGACATCATG	GGCAACTGATTCCTCCTGTTTC
<i>Sfrp2</i>	CAGCCCGACTTCTCTAC	TGGATGGTCTCATCTAGGTC
<i>Sostdc1</i>	TGGATTGGAGGAGGCTATGGAA	ACTTGCAGGCAGTGACTACTGT
<i>Tbx3</i>	CCCGAAGAAGAGGTGGAGGACG	GATGGAGACAGCAGGAGAGGAT
<i>Wnt1</i>	CTACTGGCACTGACCGCTCT	GAATCCGTCAACAGGTTTCGT
<i>Wnt11</i>	GGGCCAAGTTTTCCGATGCT	TTCGTGGCTGACAGGTAGCG
<i>Wnt2</i>	CACCCTGGACAGAGATCACA	ACAACGCCAGCTGAAGAGAT
<i>Wnt5a</i>	TCAGGACCACATGCAGTA	CTCATGGCGTTCACCACC
<i>Wnt7a</i>	TGGATGCCCGGGAGATC	CCGACCCGCCTCGTTATT
<i>Wnt7b</i>	TTCTGGAGGACCGCATGAA	GGTCCAGCAAGTTTTGGTGGTA
<i>Wnt8a</i>	AACGGTGAATTGTCTGAG	GGTGACTGCGTACATGATGG